Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Available Volunteer Opportunities Bone Health Education Presenter – Virtual Bone Health Education Volunteers work together with the Community Engagement Coordinators and are an integral part in the planning and facilitating […]

Risk Factors At least 1 in 3 women and 1 in 5 men will break a bone from osteoporosis. Did you know? Fractures from osteoporosis are more common than heart […]

Available Volunteer Opportunities Call for Nominations – Board of Directors Osteoporosis Canada (OC), a registered charity, is the only national organization serving people who have, or are at risk for, […]

DIAGNOSIS The importance of a comprehensive fracture risk assessment Insist on Assessment Osteoporosis often goes undiagnosed until a bone fractures, and is therefore commonly referred to as “the silent thief”. […]

On behalf of Osteoporosis Canada’s Scientific Advisory Consultants and Osteoporosis Canada, we would like to announce this year’s Lindy Fraser Award winner as chosen by the members of the SAC. […]

BC ADVOCACY Osteoporosis Canada together with British Columbia Coalition of Osteoporosis Physicians (BCCOP) and Medicines Access Coalition – BC (MedAccess BC) are working together to advocate for British Columbians at […]

Privacy Policy Our Commitment Osteoporosis Canada is committed to protecting the privacy of the personal information of its members, customers and other stakeholders. We value the trust of those we deal […]